Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	SEK 8.100	+3.32%	4,782
15/10/26	SEK 7.840	-0.25%	1,442
14/10/26	SEK 7.860	-5.53%	7,268
13/10/26	SEK 8.320	-3.26%	7,096
12/10/26	SEK 8.600	-5.29%	14,762

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Annexin Pharmaceuticals AB

Company calendar

Market Closed - Nasdaq Stockholm 20:00:00 16/10/2026 +04			5-day change	1st Jan Change
8.100 ^SEK	+3.32%		-10.79%	-59.09%

09-25	12 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
09-22	16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW

Market Cap	70.62M 7.13M 6.34M 5.87M 5.35M 10.09M 677M 10.25M 27.69M 353M 26.76M 26.19M 1.13B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	70.62M 7.13M 6.34M 5.87M 5.35M 10.09M 677M 10.25M 27.69M 353M 26.76M 26.19M 1.13B	EV / Sales 2026 *	1.53x	EV / Sales 2027 *	2.13x
Free-Float	54.78%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ANNX	Delayed
Deutsche Boerse AG	Q910	Delayed

09-25	12 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
09-22	16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
09-17	Annexin Pharmaceuticals Doses First Patient in Expanded Retinal Vein Occlusion Trial	MT
09-17	Annexin Pharmaceuticals AB Treats First Patient With Vanexin Following Anti-VEGF Injection In The NEXUS Study	CI
08-21	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	Annexin Pharmaceuticals Expands Study on Retinal Vein Occlusion Drug Candidate	MT
08-21	Annexin Pharmaceuticals Advances the Nexus Study to Include Patients Who Received an Anti-Vegf Injection	CI
08-20	Annexin Pharmaceuticals AB Receives The International Nonproprietary Name Vanexin For The Drug Candidate ANXV	CI
07-21	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
07-16	Calendar, Thursday, July 16	FW
06-23	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW

Annexin Pharmaceuticals AB Stock

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Valuation: Annexin Pharmaceuticals AB

Chart: Annexin Pharmaceuticals AB

Latest news: Annexin Pharmaceuticals AB

Press Releases: Annexin Pharmaceuticals AB

News in other languages: Annexin Pharmaceuticals AB

Quotes and Performance

Price Extremes

Managers and Directors: Annexin Pharmaceuticals AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

09-17	First patient treated with vanexin following anti-VEGF injection in the NEXUS study	AQ
09-10	Annexin Pharmaceuticals to Present at Investing in Life Science on September 22	AQ
08-21	Annexin advances the NEXUS study to include patients who received an anti-VEGF injection	AQ
08-20	Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV	AQ
07-21	Annexin updates on nine patients treated in NEXUS study	AQ

1 day	+3.32%
1 week	-10.79%
Current month	-8.16%
1 month	-35.46%
3 months	-37.45%
6 months	-45.45%
Current year	-59.09%

1 week	7.6	9.34
1 month	7.6	11.95
Current year	7.6	23.6
1 year	7.6	29.8
3 years	7.6	97.6
5 years	7.6	162
10 years	7.6	1,320

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	01/01/2019
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	01/01/2016
Susanne Andersson DFI	Director of Finance/CFO	55	11/04/2023

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	01/01/2017
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	01/01/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB	+3.32%	-10.79%	-70.00%	-88.05%	7.13M
WUXI APPTEC CO., LTD.	-6.60%	-8.56%	+49.38%	+63.51%	65B
LONZA GROUP AG	+0.03%	+5.56%	+9.10%	+69.05%	51.2B
ARGENX SE	-4.09%	-0.11%	+2.22%	+53.15%	51.19B
IQVIA HOLDINGS INC.	-1.53%	+2.70%	+30.48%	+34.12%	43.93B
BEONE MEDICINES AG	-1.34%	+4.12%	+16.64%	+115.13%	41.96B
REVOLUTION MEDICINES, INC.	-5.97%	-6.22%	+228.95%	+454.22%	38.14B
CELLTRION, INC.	+6.53%	+8.02%	+16.40%	+53.41%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	-3.70%	25.2B
GENMAB A/S	-1.07%	+2.33%	+19.43%	+9.98%	22.5B
Average	-1.16%	-1.39%	+33.97%	+76.08%	37.24B
Weighted average by Cap.	-2.20%	-0.50%	+44.24%	+96.53%

	2026 *	2027 *
Net sales	46.3M 4.68M 4.16M 3.85M 3.5M 6.61M 444M 6.72M 18.15M 232M 17.55M 17.17M 738M	33.1M 3.34M 2.97M 2.75M 2.51M 4.73M 317M 4.8M 12.98M 166M 12.54M 12.28M 528M
Net income	-11.5M -1.16M -1.03M -957K -870K -1.64M -110M -1.67M -4.51M -57.51M -4.36M -4.27M -183M	-24.9M -2.51M -2.23M -2.07M -1.88M -3.56M -239M -3.61M -9.76M -125M -9.44M -9.24M -397M
Net Debt	-	-